Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells

This publication has 76 references indexed in Scilit:

• Hsp90 Inhibitors Are Efficacious against Kaposi Sarcoma by Enhancing the Degradation of the Essential Viral Gene LANA, of the Viral Co-Receptor EphA2 as well as Other Client Proteins
  PLOS Pathogens, 2012
• STAR: ultrafast universal RNA-seq aligner
  Bioinformatics, 2012
• Fiji: an open-source platform for biological-image analysis
  Nature Methods, 2012
• Broad action of Hsp90 as a host chaperone required for viral replication
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
• Ensembl Genomes: an integrative resource for genome-scale data from non-vertebrate species
  Nucleic Acids Research, 2011
• A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
  Clinical Cancer Research, 2011
• SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
  Blood, 2009
• Heat Shock Protein 90 Inhibitors Prolong Survival, Attenuate Inflammation, and Reduce Lung Injury in Murine Sepsis
  American Journal of Respiratory and Critical Care Medicine, 2007
• Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance
  Genes & Development, 2007
• Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks
  Genome Research, 2003